In the U.S., Alzheimer’s clinical trials are largely limited to fluent English speakers, which leaves millions of patients without the opportunity to participate and scientists without diverse data.
(Image credit: Richard Bailey/Getty Images)
In the U.S., Alzheimer’s clinical trials are largely limited to fluent English speakers, which leaves millions of patients without the opportunity to participate and scientists without diverse data.
(Image credit: Richard Bailey/Getty Images)